Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

The purpose of this study is to determine the safety and effectiveness of TNX-650 for Injection when administered to patients with refractory Hodgkin's lymphoma.

lymphoma
stanford v regimen
refractory hodgkin lymphoma
platelet count
  • 19 views
  • 07 Nov, 2020
  • 2 locations
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV) for up to one year. The primary objective of the trial is to show efficacy of the …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy

The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy. Nivolumab is highly effective and well tolerated

nivolumab
lymphoma
avid
  • 4 views
  • 18 Apr, 2021
  • 1 location
Study of Tinostamustine First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

t-cell prolymphocytic leukemia
sezary syndrome
angioimmunoblastic t-cell lymphoma
peripheral t-cell lymphoma
lymphoma
  • 0 views
  • 14 Jun, 2021
  • 26 locations
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

This is a two-stage, Phase II clinical trial for patients with relapsed or refractory Hodgkin Lymphoma. The purpose of stage I is to evaluate whether treatment with the study drug decitabine in

lymphoma
cell transplantation
chemotherapy regimen
refractory hodgkin lymphoma
  • 3 views
  • 22 Jan, 2021
  • 1 location
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

This study is being done to test the safety and effectiveness of pembrolizumab followed by radiation therapy in Hodgkin lymphoma. The purpose of this study is to determine how effective combining the research drug, pembrolizumab, with a targeted form of radiation therapy known as involved site radiotherapy can be in …

classical hodgkin lymphoma
refractory hodgkin lymphoma
granulocyte colony stimulating factor
lymphoma
chemotherapy regimen
  • 61 views
  • 25 Jan, 2021
  • 9 locations
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

LCCC1852-ATL is a prospective pilot study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).

  • 0 views
  • 26 Jan, 2021
  • 1 location
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

classical hodgkin lymphoma
carbon monoxide
lymphoma
refractory hodgkin lymphoma
measurable disease
  • 56 views
  • 10 Feb, 2021
  • 10 locations
PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction therapy.

  • 0 views
  • 26 Apr, 2021
  • 3 locations
Brentuximab Vedotin Cyclosporine and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

This phase I trial studies the side effects and best dose of brentuximab vedotin and cyclosporine when given together with verapamil hydrochloride in treating patients with Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a …

  • 9 views
  • 28 Jan, 2021
  • 1 location